BACKGROUND The aim of this study was to evaluate the success of selective intraarterial radionuclide therapy (SIRT) with Yttrium-90 (Y-90) microspheres in liver metastases of different tumors. We also interpreted the contribution of SIRT to survival times according to responder- non responder and hepatic- extra hepatic disease. METHODS The clinical and follow-up data of 124 patients who were ...

BACKGROUND & OBJECTIVES Radioimmunotherapy is extensively being used for the treatment of non-Hodgkin's lymphoma (NHL). Use of rituximab, a chimeric anti-CD20 antibody directed against the CD20 antigen in combination with suitable beta emitters is expected to result in good treatment response by its cross-fire and bystander effects. The present work involves the conjugation of p-isothiocyanatob...

BACKGROUND In this retrospective study, we investigated the efficacy and safety of radioimmunotherapy with (90)Yttrium- ibritumomab tiuxetan ((90)Y-RIT) in 9 patients with recurrent follicular lymphoma (FL) who were treated in a consolidation setting after having achieved complete (CR) or partial remission (PR) with Fludarabine, Cyclophosphamide and Rituximab (FCR). METHODS The median age was...

BACKGROUND the characteristics of (90)Y, suitable for therapy, are denoted by the lack of γ-emission. Alternative methods, using analogues labelled with (111)In or (86)Y, are generally applied to image (90)Y-conjugates, with some inevitable drawbacks. New generation SPECT/CT image systems offer improved Bremsstrahlung images. The intent of this brief communication is to show that high quality (...

90 Y is traditionally considered as a pure β – emitter. However, the decay of this radionuclide has a minor branch to the 0 + first excited state of 90 Zr at 1.76 MeV, that is followed by a β + /β – emission. This internal pair production has been largely studied in the past because it is generated by a rare electric monopole transition (E0) between the states 0 + /0 + of 90 Zr. The positronic ...